BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36402786)

  • 21. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
    Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
    Trafalis DT; Polonifi A; Dalezis P; Nikoleousakos N; Katsamakas S; Sarli V
    Chem Biol Drug Des; 2017 Nov; 90(5):854-866. PubMed ID: 28432813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
    Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
    Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G
    Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
    Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LDH-A inhibitors as remedies to enhance the anticancer effects of PARP inhibitors in ovarian cancer cells.
    Xiang J; Zhou L; He Y; Wu S
    Aging (Albany NY); 2021 Dec; 13(24):25920-25930. PubMed ID: 34919531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
    Ray-Coquard I; Vanacker H; Le Saux O; Tredan O
    EBioMedicine; 2020 Nov; 61():103046. PubMed ID: 33038760
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    Wu Y; Xu S; Cheng S; Yang J; Wang Y
    J Ovarian Res; 2023 Jan; 16(1):6. PubMed ID: 36611214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
    Kanakkanthara A; Hou X; Ekstrom TL; Zanfagnin V; Huehls AM; Kelly RL; Ding H; Larson MC; Vasmatzis G; Oberg AL; Kaufmann SH; Mansfield AS; Weroha SJ; Karnitz LM
    Cancer Res; 2022 Jan; 82(2):307-319. PubMed ID: 34810199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.
    Hou D; Xu G; Zhang C; Li B; Qin J; Hao X; Liu Q; Zhang X; Liu J; Wei J; Gong Y; Liu Z; Shao C
    Cell Death Dis; 2017 Oct; 8(10):e3070. PubMed ID: 28981112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
    Hou D; Liu Z; Xu X; Liu Q; Zhang X; Kong B; Wei JJ; Gong Y; Shao C
    Redox Biol; 2018 Jul; 17():99-111. PubMed ID: 29684820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
    Konstantinopoulos PA; Matulonis UA
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):997-1010. PubMed ID: 30390770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
    Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
    Marom I; Lavie O; Ostrovsky L; Kugelman N; Schmidt M; Segev Y
    Harefuah; 2020 Mar; 159(3):175-180. PubMed ID: 32186787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The roles and limitations of bevacizumab in the treatment of ovarian cancer.
    Nakai H; Matsumura N
    Int J Clin Oncol; 2022 Jul; 27(7):1120-1126. PubMed ID: 35477830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    Miller RE; El-Shakankery KH; Lee JY
    J Gynecol Oncol; 2022 May; 33(3):e44. PubMed ID: 35320891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M; Coleman RL; Westin SN
    Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.